Behcet disease

Last updated: September 11, 2023

CME information and disclosurestoggle arrow icon

To see contributor disclosures related to this article, hover over this reference: [1]

Physicians may earn CME/MOC credit by reading information in this article to address a clinical question, and then completing a brief evaluation, in which they will identify their question and report the impact of any information learned on their clinical practice.

AMBOSS designates this Internet point-of-care activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

For answers to questions about AMBOSS CME, including how to redeem CME/MOC credit, see "Tips and Links" at the bottom of this article.

Summarytoggle arrow icon

Behcet disease is a type of variable vessel vasculitis that most commonly affects young adults (20–40 years of age) from the Mediterranean region to eastern Asia. Patients typically present with recurrent, painful oral and/or genital ulcerations; uveitis and erythema nodosum are also common in patients with Behcet disease. Diagnosis is based on clinical features, but diagnostic studies (e.g., Doppler ultrasound, MRA head) are required to assess for end-organ damage and exclude differential diagnoses (e.g., aphthous stomatitis, reactive arthritis). Management is based on the affected organs and disease severity, but often involves immunosuppressive agents (e.g., glucocorticoids, azathioprine) and colchicine.

Epidemiologytoggle arrow icon

  • Most commonly affects individuals from the Mediterranean region to eastern Asia, with the highest prevalence observed in Turkey and Japan [2]
  • Peak incidence: 20–40 years of age
  • >

Epidemiological data refers to the US, unless otherwise specified.

Etiologytoggle arrow icon

  • Possible autoimmune and infectious triggers (e.g., precipitating HSV or parvovirus infection) [3]
  • Strong HLA-B51 association

Pathophysiologytoggle arrow icon

Clinical featurestoggle arrow icon

PATHERGY: Positive pathergy test, Aphthous oral ulcers, Thrombosis (arterial and venous), Hemoptysis (pulmonary artery aneurysm), Eye lesions (uveitis, retinal vasculitis), Recurrent Genital ulcers, Young at presentation (3rd decade)

Diagnosticstoggle arrow icon

General principles [2][7]

  • Diagnosis is primarily clinical.
  • Diagnostic criteria may be used to establish a diagnosis.
  • Diagnostic studies may be required to assess for end-organ damage and to exclude differential diagnoses.

Rule out other conditions before starting potentially unnecessary and harmful immunosuppressive therapy.

Neuro-Behcet syndrome, vascular disease (e.g., pulmonary artery aneurysms), and GI disease are the main causes of mortality in Behcet disease and should be promptly identified and treated. [2][7]

Diagnostic criteria

International Study Group diagnostic criteria for Behcet disease [2][9]
Mandatory criterion
  • Recurrent (i.e., ≥ 3 episodes within a 12-month period) oral aphthous ulcers
Additional criteria
A diagnosis may be established in patients who fulfill the mandatory criterion PLUS ≥ 2 of the additional criteria.

Laboratory studies [2][7]

Imaging studies [7]

Consider imaging studies based on suspected conditions.

Differential diagnosestoggle arrow icon

Clinical features of Behcet disease may also be present in several other conditions, e.g.: [2][7]

The differential diagnoses listed here are not exhaustive.

Treatmenttoggle arrow icon

Approach [4][12][13]

  • Nonsevere disease
    • Consult a rheumatologist and other specialists as required.
    • Choice of therapy is based on the type of lesions.
  • Severe disease : Consult a specialist (e.g., neurology, ophthalmology, surgery) and start treatment early to prevent permanent damage. [13]

Up to one-third of patients with GI involvement require emergency surgery as a result of GI perforation, major bleeding, or obstruction. [13]

Pharmacotherapy [12]

Patients with severe disease usually require aggressive management with a combination of high-dose glucocorticoids and other immunosuppressive agents.

Supportive care

Referencestoggle arrow icon

  1. Davatchi F, Chams-Davatchi C, Shams H, et al. Behcet’s disease: epidemiology, clinical manifestations, and diagnosis. Expert Rev Clin Immunol. 2016; 13 (1): p.57-65.doi: 10.1080/1744666x.2016.1205486 . | Open in Read by QxMD
  2. Habibagahi M PhD, Habibagahi Z Md, Saidmardani SM Md, Sadeghian F Md. No Definite Association between Human Parvovirus B19 Infection and Behçet Disease.. Iranian journal of medical sciences. 2015; 40 (6): p.493-500.
  3. Jagdish R Nair, Robert J Moots. Behcet's disease. Clin Med (Northfield Il). 2017; 17 (1): p.71-77.doi: 10.7861/clinmedicine.17-1-71 . | Open in Read by QxMD
  4. Kokturk A. Clinical and Pathological Manifestations with Differential Diagnosis in Behçet's Disease.. Pathology research international. 2012; 2012: p.690390.doi: 10.1155/2012/690390 . | Open in Read by QxMD
  5. Antonio Greco, Armando De Virgilio, Massimo Ralli, Andrea Ciofalo, Patrizia Mancini, Giuseppe Attanasio, Marco de Vincentiis, Alessandro Lambiase. Behçet's disease: New insights into pathophysiology, clinical features and treatment options. Autoimmun Rev. 2018; 17 (6): p.567-575.doi: 10.1016/j.autrev.2017.12.006 . | Open in Read by QxMD
  6. Ambrose NL, Haskard DO. Differential diagnosis and management of Behçet syndrome. Nat Rev Rheumatol. 2012; 9 (2): p.79-89.doi: 10.1038/nrrheum.2012.156 . | Open in Read by QxMD
  7. Saip S, Akman-Demir G, Siva A. Neuro-Behçet syndrome. Handb Clin Neurol. 2014; 121: p.1703-1723.doi: 10.1016/B978-0-7020-4088-7.00110-3 . | Open in Read by QxMD
  8. International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease.. Lancet. 1990; 335 (8697): p.1078-80.
  9. Kaya TI. Genetics of Behçet's Disease. Pathology Research International. 2012; 2012: p.1-6.doi: 10.1155/2012/912589 . | Open in Read by QxMD
  10. Hiller N, Lieberman S, Chajek-Shaul T, Bar-Ziv J, Shaham D. Thoracic Manifestations of Behçet Disease at CT. RadioGraphics. 2004; 24 (3): p.801-808.doi: 10.1148/rg.243035091 . | Open in Read by QxMD
  11. Yazici Y, Hatemi G, Bodaghi B, et al. Behçet syndrome. Nat Rev Dis Primers. 2021; 7 (1).doi: 10.1038/s41572-021-00301-1 . | Open in Read by QxMD
  12. Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behçet’s syndrome. Ann Rheum Dis. 2018.doi: 10.1136/annrheumdis-2018-213225 . | Open in Read by QxMD
  13. $Contributor Disclosures - Behcet disease. All of the relevant financial relationships listed for the following individuals have been mitigated: Alexandra Willis (copyeditor, was previously employed by OPEN Health Communications). None of the other individuals in control of the content for this article reported relevant financial relationships with ineligible companies. For details, please review our full conflict of interest (COI) policy:.

Icon of a lock3 free articles remaining

You have 3 free member-only articles left this month. Sign up and get unlimited access.
 Evidence-based content, created and peer-reviewed by physicians. Read the disclaimer